Physician profile
Rose Munoz
NPI 1932463148
$883.55
in general payments reported to CMS, 2019-2025
7 companies · $142 in 2025
The $142 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $126 · 2022: $209 · 2023: $85.29 · 2024: $321 · 2025: $142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $548.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $548.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $285.00 | 2022-2025 | Tremfya, Remicade, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $266.53 | 2021-2024 | Xifaxan, Plenvu |
| Abbvie INC. | $181.72 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.65 | 2021-2022 | |
| Gilead Sciences, INC. | $36.70 | 2021-2022 | |
| Intercept Pharmaceuticals, INC. | $35.90 | 2021-2023 | Ocaliva |
| Csl Behring | $33.05 | 2023 | Kcentra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rose Munoz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.